tetano
Editor, Senior Moderator
Pediatr Rep
. 2021 Jul 2;13(3):363-382.
doi: 10.3390/pediatric13030045.
Innate Immunity in Children and the Role of ACE2 Expression in SARS-CoV-2 Infection
Mario Dioguardi[SUP] 1 [/SUP], Angela Pia Cazzolla[SUP] 1 [/SUP], Claudia Arena[SUP] 1 [/SUP], Diego Sovereto[SUP] 1 [/SUP], Giorgia Apollonia Caloro[SUP] 2 [/SUP], Antonio Dioguardi[SUP] 3 [/SUP], Vito Crincoli[SUP] 4 [/SUP], Luigi Laino[SUP] 5 [/SUP], Giuseppe Troiano[SUP] 1 [/SUP], Lorenzo Lo Muzio[SUP] 1 [/SUP]
Affiliations
Abstract
COVID-19 (Coronavirus Disease 2019) is an emerging viral disease caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which leads to severe respiratory infections in humans. The first reports came in December 2019 from the city of Wuhan in the province of Hubei in China. It was immediately clear that children developed a milder disease than adults. The reasons for the milder course of the disease were attributed to several factors: innate immunity, difference in ACE2 (angiotensin-converting enzyme II) receptor expression, and previous infections with other common coronaviruses (CovH). This literature review aims to summarize aspects of innate immunity by focusing on the role of ACE2 expression and viral infections in children in modulating the antibody response to SARS-CoV-2 infection. This review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles deemed potentially eligible were considered, including those dealing with COVID-19 in children and providing more up-to-date and significant data in terms of epidemiology, prognosis, course, and symptoms, focusing on the etiopathogenesis of SARS-CoV-2 disease in children. The bibliographic search was conducted using the search engines PubMed and Scopus. The following search terms were entered in PubMed and Scopus: COVID-19 AND ACE2 AND Children; COVID-19 AND Immunity innate AND children. The search identified 857 records, and 18 studies were applicable based on inclusion and exclusion criteria that addressed the issues of COVID-19 concerning the role of ACE2 expression in children. The scientific literature agrees that children develop milder COVID-19 disease than adults. Milder symptomatology could be attributed to innate immunity or previous CovH virus infections, while it is not yet fully understood how the differential expression of ACE2 in children could contribute to milder disease.
Keywords: ACE-2; COVID-19; SARS-CoV-2; adolescents; children; coronavirus.
. 2021 Jul 2;13(3):363-382.
doi: 10.3390/pediatric13030045.
Innate Immunity in Children and the Role of ACE2 Expression in SARS-CoV-2 Infection
Mario Dioguardi[SUP] 1 [/SUP], Angela Pia Cazzolla[SUP] 1 [/SUP], Claudia Arena[SUP] 1 [/SUP], Diego Sovereto[SUP] 1 [/SUP], Giorgia Apollonia Caloro[SUP] 2 [/SUP], Antonio Dioguardi[SUP] 3 [/SUP], Vito Crincoli[SUP] 4 [/SUP], Luigi Laino[SUP] 5 [/SUP], Giuseppe Troiano[SUP] 1 [/SUP], Lorenzo Lo Muzio[SUP] 1 [/SUP]
Affiliations
- PMID: 34287338
- DOI: 10.3390/pediatric13030045
Abstract
COVID-19 (Coronavirus Disease 2019) is an emerging viral disease caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which leads to severe respiratory infections in humans. The first reports came in December 2019 from the city of Wuhan in the province of Hubei in China. It was immediately clear that children developed a milder disease than adults. The reasons for the milder course of the disease were attributed to several factors: innate immunity, difference in ACE2 (angiotensin-converting enzyme II) receptor expression, and previous infections with other common coronaviruses (CovH). This literature review aims to summarize aspects of innate immunity by focusing on the role of ACE2 expression and viral infections in children in modulating the antibody response to SARS-CoV-2 infection. This review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles deemed potentially eligible were considered, including those dealing with COVID-19 in children and providing more up-to-date and significant data in terms of epidemiology, prognosis, course, and symptoms, focusing on the etiopathogenesis of SARS-CoV-2 disease in children. The bibliographic search was conducted using the search engines PubMed and Scopus. The following search terms were entered in PubMed and Scopus: COVID-19 AND ACE2 AND Children; COVID-19 AND Immunity innate AND children. The search identified 857 records, and 18 studies were applicable based on inclusion and exclusion criteria that addressed the issues of COVID-19 concerning the role of ACE2 expression in children. The scientific literature agrees that children develop milder COVID-19 disease than adults. Milder symptomatology could be attributed to innate immunity or previous CovH virus infections, while it is not yet fully understood how the differential expression of ACE2 in children could contribute to milder disease.
Keywords: ACE-2; COVID-19; SARS-CoV-2; adolescents; children; coronavirus.